Renovaro Inc
RENB1.420USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
251.90MMarket Cap
LossP/E TTM
More Details of Renovaro Inc Company
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Renovaro Inc Info
Ticker SymbolRENB
Company nameLunai Bioworks Inc
IPO dateNov 18, 2014
CEOWeinstein (David)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 18
Address2080 Century Park East, Suite 906
CityLOS ANGELES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code90067
Phone14539179840
Website
Ticker SymbolRENB
IPO dateNov 18, 2014
CEOWeinstein (David)
Company Executives of Renovaro Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Feb 2
Updated: Mon, Feb 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
Gumrukcu (Serhat)
5.35%
The Vanguard Group, Inc.
2.12%
Other
61.59%
Shareholders
Shareholders
Proportion
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
Gumrukcu (Serhat)
5.35%
The Vanguard Group, Inc.
2.12%
Other
61.59%
Shareholder Types
Shareholders
Proportion
Corporation
31.30%
Individual Investor
8.09%
Investment Advisor
2.88%
Hedge Fund
1.12%
Investment Advisor/Hedge Fund
0.78%
Research Firm
0.03%
Other
55.79%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
145
2.48M
10.61%
+647.45K
2025Q3
144
2.83M
12.20%
+559.32K
2025Q2
156
65.41M
35.65%
+4.54M
2025Q1
161
103.48M
60.94%
+42.30M
2024Q4
155
103.71M
63.86%
+49.62M
2024Q3
149
51.49M
35.21%
-1.80M
2024Q2
151
51.88M
36.43%
+6.39M
2024Q1
154
44.98M
32.23%
+3.81M
2023Q4
151
44.01M
67.51%
+217.77K
2023Q3
146
41.12M
71.08%
+1.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RS Group ApS
3.54M
15.1%
+1.86M
+110.33%
Oct 03, 2025
Lakysa Ventures, Inc
2.27M
9.67%
+116.68K
+5.43%
Oct 03, 2025
PasecoApS
1.45M
6.17%
-1.25M
-46.44%
Oct 03, 2025
Gumrukcu (Serhat)
1.25M
5.35%
--
--
Dec 05, 2025
The Vanguard Group, Inc.
517.63K
2.21%
+25.16K
+5.11%
Sep 30, 2025
William (Anderson Wittekind)
476.63K
2.03%
--
--
Dec 05, 2025
Millennium Management LLC
202.63K
0.86%
-12.33K
-5.74%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
127.28K
0.54%
-129.27K
-50.39%
Sep 30, 2025
Geode Capital Management, L.L.C.
126.54K
0.54%
+24.95K
+24.56%
Sep 30, 2025
Weinstein (David Hershel)
105.00K
0.45%
+20.00K
+23.53%
Oct 03, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Sep 24, 2025
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Sep 24, 2025
Merger
10→1
